Indaptus Therapeutics Holds Annual Meeting, Elects Directors
Ticker: INDP · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, annual-meeting, stockholder-vote
TL;DR
Indaptus held its annual meeting, re-elected directors, and approved the equity plan. Standard stuff.
AI Summary
Indaptus Therapeutics, Inc. announced on June 6, 2024, that it held its 2024 Annual Meeting of Stockholders. During the meeting, stockholders elected two Class II directors, approved an amendment to the company's 2021 Equity Incentive Plan, and ratified the appointment of WithumSmith+Brown, PC as its independent registered public accounting firm for the fiscal year ending December 31, 2024.
Why It Matters
The election of directors and approval of equity plans are standard corporate governance actions that can impact future executive compensation and board composition.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters such as director elections and ratification of auditors, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Registrant
- June 6, 2024 (date) — Date of Annual Meeting
- 2024 Annual Meeting of Stockholders (event) — Meeting held
- 2021 Equity Incentive Plan (plan) — Approved amendment
- WithumSmith+Brown, PC (company) — Independent registered public accounting firm
- December 31, 2024 (date) — Fiscal year end for auditor appointment
FAQ
Who were the Class II directors elected at the meeting?
The filing states that two Class II directors were elected, but their names are not specified in this 8-K summary.
What specific amendment was made to the 2021 Equity Incentive Plan?
The filing indicates an amendment to the 2021 Equity Incentive Plan was approved, but the details of the amendment are not provided in this summary.
What is the primary business of Indaptus Therapeutics, Inc.?
Indaptus Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When is the fiscal year end for which WithumSmith+Brown, PC was appointed as auditor?
WithumSmith+Brown, PC was appointed as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
What was the former name of Indaptus Therapeutics, Inc.?
The former name of Indaptus Therapeutics, Inc. was Intec Parent Inc., with a date of name change on April 14, 2021.
Filing Stats: 846 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-06-07 16:30:38
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INDP Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex10-1.htm (EX-10.1) — 287KB
- 0001493152-24-023119.txt ( ) — 574KB
- indp-20240606.xsd (EX-101.SCH) — 3KB
- indp-20240606_lab.xml (EX-101.LAB) — 33KB
- indp-20240606_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 7, 2024 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer